http://stocktwits.com/bigbigwin/message/590194015

I'm looking forward to the up-list.

Six digits is very telling, especially at this level.

The UK's recently announced interest to bring modular closed-loop manufacturing closer to patient care sites has the final version of Flaskworks name written all over it imho. Where else would that idea have come from? It's not only, that there has been a review backlog, which has been substantially cleared out, but also the agency has had its own learning curve mixed in as part of its transformation efforts.

Let's keep in mind, there's been a lot of support from various public advocacy groups, including, but limited to a UK MP, who was personally touched by GBM, Ashkan, who's won recognition for his contributions to the field, and lastly the UK's interest to be a center of excellence for medical innovation globally. If we factor in all of the evolving guidance, which have coincided with the advancements introduced by NWBO, it's hard to fathom a lessor challenging treatment modality, if indeed the interest of the UK is real. It could very well be, that there's an effort to roll marketing authorization, commerical manufacturing, and NICE reimbursement in for a one and done landing, and establish Dcvax as the center piece for the UK's bold ambitions. Les had said, "we're going to be a much different company in the fall."

Newman - We're at .28. What's the business model here for MM's? I suspect we're low enough to have provided shorts and opportunity to cover their positions and move on, especially with possible news that could drop anytime. Certainly, there's no money being made.

tumnelvision - Thanks for a well thought through contribution with data behind it, as it's certainly long overdue here. It would be interesting to compare the degree of unmet need of those approved treatments you cited against DCVAX.

Accepted

Notsure2 - Exactly, at one point, even sheep minds will discover the difference between treatments that are not only ineffective, but more importantly criminal.
I had to go there. Spoke to our new condo manager Christopher yesterday. He said he has an identical twin brother, who has served in the military for 10 years. Christopher described his own health as being great. No issues at all. His identical brother on the other hand, since begrudgingly acquiescing to taking the COVID-19 vaccine has been in and out of the hospital. Further, his brother knows of others among his rank who have suffered no less in degree. It should be simple to expand to extrapolate the REAL numbers who have suffered the same fate, if an honest regime would not systemically shadow ban the numbers all available to those of us who care to do simple DD.

You can't dupe cancer patients, because unlike an invisible virus, which can't be discerned from others through the misuse of PCR's, which can not detect infection, Merck or whichever company that wants a legitimate piece of the cancer market will have to actually put up or shut up.

Sorry for your loss.

Reefraid - Yes! Patients are treated by physicians, so I disagree that patients would abandon physician recommended treatments, particularly after the physician has knowledge of the UK approval to add to the treatment conversation. No, physicians just don't go to a graph that shows mOS as their comprehensive consideration. How many times has dstock shared ad nauseum, today's advanced use of biomarker data to determine what treatment option would best serve the patient?

So now the new narrative is that a UK approval would not attract patients far away i.e. U.S. for the huge out of pocket cost? Really? We're not talking about teenage acne problems. You're dead in 9 months typically, and that includes acute suffering along the way. Maybe you would personally opt for SOC, but faced with eminent death, most people take desperate measures for a chance to live.

Doc Logic - The first approval establishes DCVAX as a commercial treatment, obviously, which is paramount for large funds as the basis for going long and large. But more importantly, first, it sets the stage for LP to advance her up-listing strategy, which she has had years to prepare and formulate..

Doctors prescribe treatments, they don't happen in a vacuum.

Yesterday, it was flipper putting words in my mouth, suggesting I would want to see $3-$4 after approval. Now you're suggesting, that I expected an expedited review. You have me confused with someone else. But feel free to switch the subject matter.

IMHO, if companies were given reign to adjust for acute illegal share price suppression, that uses a form of fair market value adjustment, as a floor, from which it can negotiate potential BO negotiations, we would see insurmountable pressure to arrest illegal spoofing.. naked shorting etc.

Interesting. But then again, Manibio has more faith in the inept bureaucracy that can't even get it's right hand to work with its left.

Further, there's *good reason why the MHRA would license, and obviously, therefore prioritize the review, as an in-house drug(pill). Basically, you're saying how come the MHRA knows, which review path it's taking for drug it's reviewing for itself? It's Elli Lilly on top of everything else. Elli Lilly has enormous influence over MHRA, but you didn't know that.

*Severe unmet need and addressable marker size!

ccie1024 - I don't know what you were responding to, but it's important to note, that the MHRA has "licensed" the Alzheimer's drug by entering a public/private partnership which obviously removes the drug's consideration timeline outside the guidance given to private corporate applications.

A pill is straight forward. Again, because it doesn't involve the kind of commited MHRA resources for the kinds of inspections that Dcvax relatively requires, it should be obvious to understand how the MHRA was able, and willing to provide a straight answer to the company, as to what specific pathway was chosen. Moreover, if this is the same Alzheimer's drug ccie posted about following yours, it says that the MHRA is LICENSING the drug. In that case, it's a public/private partnership. It doesn't need further explanation.

Common use some common sense man. You're talking about a pill, not complex cell therapy with complex manufacturing.

Yep, it would definitely keep BP honest. Imagine, they would actually need to produce treatments to benefit patients, and not more poison dressed up as a solution.

LP made it a point to say how "uncharacteristic" NICE's engagement with NWBO has been, as she used words like cooperative, engaging, and ongoing discussions. People can look at the glass half empty, but for an inept bureaucracy, as I know them all to be, including corrupt, that's one hell of a reason to see the glass half full. It's a war of attrition in my view, as a small prevenue biotech was not supposed to turn the failed cancer space on its head. We're seeing the remaining actions of a flailing status quo that's on life support, which has resorted to breaking the law in plainsight, as desperation has set in. Come on now, sp @ .27? Really? Normal? Really? It's no coincidence, seriously, that during this same period, we have seen BP's efforts to remain relevant disintegrate through multiple trial failures. Imagine a last ditch SC administration application for extension of a patent turning out to increase mortality, and the Senior Director literally mischaracterizing the catastrophic news, as something to overlook 🤔 🤯 I choose to remain focused on the landscape, within which maginal treatments have become blockbusters, not because they deserve such a titles, but because BPs have kept the market desperate enough, and dumbeddown enough, to accept just about anything, especially as people are faced with death.

As expected, NVCR down 25% in the last week. They give pump a whole new meaning, as a company, with a product that lost relevance long ago.

Newman - Are you documenting and sending the data to the relevant parties as ATL did yesterday?

Doc Logic - While we bear legitimate frustrations, I think of the current circumstances from a big picture standpoint. 10 years of R&D and a $billion has typically delivered a mature product on approval. Setting aside conventional drugs, like pills, we can point to today's more sophisticated cancer therapies, and it's pretty much the same story. So while investors have been unable to enjoy the fair value of what has been created, time for Dcvax, as a platform has not stood still. Take today's Henry post pointing out 6 new patents gained as recent as Dec 2023. At the end of the day having an approved product that could potentially lose its relevance quickly is the last thing any long term investor would want. NWBO has been quietly, while Political Scientists are looking at vintage clothes from 20 years ago, as dstock keeps pointing out are missing a revolutionary approach, which hasn't been seen, or undertaken before.

Flipper - Really?

Roman516 - Yep, the same Deep State that fined Citadel $1 million for major reporting violations recently. There's your wink and a nod to spoofing brigade.😉

Goodguybill - The MM's have graduated to a new level of absurdity, where retail (see ATLnsider) post capturing the spoofing in real-time through screenshots and simple math. No words!

ATLnsider - Thanks!!! for sharing the red-handed capture of spoofing into the public domain in real-time, and topping it off by sharing it with the authorities and CohenMilstein!! I don't know if it was at all that common in earlier times, but it's remarkable imo, to see retail's ability to capture the crime in real-time no less. In OTHER WORDS, WHO NEEDS DISCOVERY WHEN IT'S IN EVERYONE'S FACE?

MTD could be waiting on settlement discussions among the smaller MM's. The Defendants, especially the smaller entities have their backs against the wall, as spoofing cases preceding NWBO have proven unfavorable for the financial institutions under scrutiny. While absurdity has become normalized imo, at some point, unless the oversized greed is held accountable, then the entire system is faced with the real and present danger of burning down.

Newman - This is HUGE imo! I bet Flashworks was known and pitched to the UK health authorities, as the impetus behind the formulation first introduced as a concept in late 2021. For all those who can't stop their irrational impulse to blame LP for why things take so long, look no further at how long this new initiative took to launch, and still not expected to become adapted until 2025.

When considering a biotech like $Amrn it's important to understand not only the unmet need, but also how the unmet need is perceived by providers, and more importantly patient attitudes towards compliance. While Vascepa is truly, as big a game changer as Statins were, there's a 50% drop of rate in patient compliance after 6 months, at least from what was seen in the U.S. That's one of the reasons why I sold my last position at $1.17. It's been under a buck since.

Yet the stock hasn't moved up one penny on that news.

Well said.

My issue is with the willingness of some to normalize what is clearly abnormal. We saw the current SP before DL. We had months of Scotty, like some form of tourettes blurting, "LP will never data lock!" I don't have to fire off the mesmerizing list of milestones and scientific advancements achieved by NWBO since then. But it's even more absurd, when considering how long the list of ineffective or marginal treatments are comparatively, with many side effects, including fatality making huge bundles of money, let alone approved, and still on the market no less. Saying people are so naive is generous at best.

NWBO has a case before Stein looking for relief after years of being victimized by admitted system riggers. The nature of NWBO 's business model and the lives hanging in the balance demands prioritizing, not sitting on the decision. The court is wittingly or unwittingly adding to the damage.

Han's post is reiterating what has been known obviously, if not to those who are slow, but certainly to the MHRA. I think it's ludicrous for DCVAX to take nearly as long as an immensely dangerous gene editing modality like Crispr. When I asked Gemini if Crispr causes side effects:

Danish - You have a high tolerance for cringeworthy ignorance. You're trying to reason with those who want to be right, and not those who care for the truth. I've tested the depths of cognitive dissonance here many times. It's often you'll find fact-check, as a means to shut down debate, or use as a surrogate for the kind that I'm a proponent of. Namely, that rises to the level a court would find admissable as evidence. How do you stake a claim on an intro, when no genuine interest for the supporting data is welcome, but instead met with deletion, insult, or some lazy response that satisfies their own ignorance over reality?
Keep in mind, society has reached a point where beliefs can not, for the most part, be overcome with overwhelming truth.

I didn't say anything. But I did repost. People can determine what resonates for them. They don't need your personal opinions. Get over yourself.

I wouldn't expect he could stop the manipulation either from everything I've learned in recent years. But rather, he has ties to acquire data, which is the foundation for prosecuting white collar criminality successfully.